tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

ORIC Pharmaceuticals: Promising Oncology Developments and Strategic Trials Support Buy Rating

ORIC Pharmaceuticals: Promising Oncology Developments and Strategic Trials Support Buy Rating

Analyst Soumit Roy from JonesTrading maintained a Buy rating on Oric Pharmaceuticals and keeping the price target at $17.00.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Soumit Roy has given his Buy rating due to a combination of factors that highlight ORIC Pharmaceuticals’ potential in the oncology market. One of the key reasons is the promising development of ORIC-944, which is being tested in combination with Erleada or Nubeqa for prostate cancer. The data from the Phase 1 study is expected to show a favorable safety profile and efficacy that could surpass Pfizer’s competing drug, mevro. This potential for better clinical outcomes positions ORIC-944 as a strong contender in the market.
Additionally, ORIC’s enozertinib, targeting EGFR mutations in non-small cell lung cancer, is another critical asset. Although the competition is fierce, positive data expected in late 2025 could significantly enhance ORIC’s market position. The initiation of registrational trials for both ORIC-944 and enozertinib in 2026 could further drive the company’s valuation. The anticipation of these developments, combined with the company’s current cash position, supports the Buy rating.

Roy covers the Healthcare sector, focusing on stocks such as Protara Therapeutics, CervoMed, and CG Oncology, Inc.. According to TipRanks, Roy has an average return of -18.4% and a 24.49% success rate on recommended stocks.

Disclaimer & DisclosureReport an Issue

1